Concern that Generic Antipsychotics May Lead to Rise in Off-label Prescribing to Children

3
66

Healthline reports that as five second-generation antipsychotics (SGAs) lose patent protection, Medicaid expenditures for antipsychotics are projected to be cut in half over the next five years.  But some worry that the decrease in spending may lead policymakers to lift existing restrictions on antipsychotics at a time when most SGAs are prescribed to children for off-label reasons.

Article → 

Support MIA

MIA relies on the support of its readers to exist. Please consider a donation to help us provide news, essays, podcasts and continuing education courses that explore alternatives to the current paradigm of psychiatric care. Your tax-deductible donation will help build a community devoted to creating such change.

$
Select Payment Method
Personal Info

Credit Card Info
This is a secure SSL encrypted payment.

Billing Details

Donation Total: $20 One Time

3 COMMENTS

  1. This is just a disgusting reflection of the evil society in which we currently live. “Experts hope more affordable versions of these drugs will help policymakers lift restrictions on antipsychotic medications.”

    And these need to be lifted because “67 percent of Medicaid payment claims for second generation antipsychotics represent quality of care concerns.” Including 50% poorly monitored, 41% “involved ‘wrong treatment,'” and 1/3 “involved children on too many drugs.”

    Only “8 percent of the drugs were given for medically accepted reasons.” The “vast majority of Medicaid funded antipsychotics were going to children for treatment not approved by the U.S. Food and Drug Administration.”

    And this after the United Nations confessed that “forced psychiatric treatment is torture.” All these governmently controlled children are being tortured. What is the matter with the “experts” in this country, and our government? They’ve all lost their minds.

LEAVE A REPLY